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ZebraﬁshTransmissible spongiform encephalopathies (TSEs), otherwise known as prion disorders, are fatal diseases
causing neurodegeneration in a wide range of mammalian hosts, including humans. The causative agents –
prions – are thought to be composed of a rogue isoform of the endogenous prion protein (PrP). Beyond these
and other basic concepts, fundamental questions in prion biology remain unanswered, such as the
physiological function of PrP, the molecular mechanisms underlying prion pathogenesis, and the origin of
prions. To date, the occurrence of TSEs in lower vertebrates like ﬁsh and birds has received only limited
attention, despite the fact that these animals possess bona ﬁde PrPs. Recent ﬁndings, however, have brought
ﬁsh before the footlights of prion research. Fish models are beginning to provide useful insights into the roles
of PrP in health and disease, as well as the potential risk of prion transmission between ﬁsh and mammals.
Although still in its infancy, the use of ﬁsh models in TSE research could signiﬁcantly improve our basic
understanding of prion diseases, and also help anticipate risks to public health. This article is part of a Special
Issue entitled Zebraﬁsh Models of Neurological Diseases.ncephalopathies; PrP, prion
D, Creutzfeldt–Jakob disease;
eal; p.i., post inoculation; i.c.,
raﬁsh Models of Neurological
contacted at Department of
457, Konstanz, Germany. Tel.:
Department of Pharmacology,
(AUTH), AUTH Campus, 54214
2310 997720.
(E. Málaga-Trillo),
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
1.1. Prion disorders
Prion diseases or TSEs are a group of rare but fatal neurological
disorders that affect humans and animals. Whether sporadic, inherited
or acquired, these illnesses generally correlate with the accumulation of
misfolded PrP in the brain and the appearance of widespread
neurodegeneration after long incubation times [1]. The classical
histopathological landmarks of TSEs are spongiform vacuolation,
neuronal loss and astrocytic gliosis, whereas the main clinical
manifestations in humans include progressive dementia, cerebellar
ataxia and myoclonus [2]. Interestingly, although such symptoms are
also observed in more common neurodegenerative disorders likeAlzheimer's disease (AD) and Parkinson's disease (PD), prion diseases
have received special attention because of their infectious nature and
the associated risk of epidemics.
In fact, prion diseases gained considerable notoriety in the 1990s
because of the massive outbreak of mad cow disease (bovine spongi-
form encephalopathy, BSE) in Europe and the negative impact it had on
public health and the food industry. TSEs are, however, not a recent
phenomenon. Their history dates back to the 1700s when scrapie, a
related neurological condition among sheep and goats, was ﬁrst
described in England [3]. Other TSEs in animals include chronic wasting
disease (CWD) in deer and elk, transmissible mink encephalopathy and
feline spongiform encephalopathy (FSE) [4]. The most common TSEs in
humans, Creutzfeldt–Jacob disease (CJD) and Gerstmann Sträussler
Scheinker syndrome (GSS), were discovered much later (1920s and
1930s, respectively [5]), and it was not until the 1950s that the study of
kuru, another human prion disease, set off a chain of revolutionary
discoveries that would redeﬁne the meaning of “pathogen” and push a
biological dogma against the ropes.
1.2. The nature of the infectious TSE agent
Kuruwas originally described as a neurological epidemic of the Fore
linguistic group in Papua New Guinea [2]. For some time, the disease
was believed to be infectious, and possibly transmitted during
cannibalistic rituals. Nevertheless, failure to transmit kuru to laboratory
animals led to the erroneous assumption that it had a genetic basis.
Towards 1959, remarkable similarities between kuru, CJD and scrapie
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levels [6,7]. Since scrapie had been already shown to be transmissible
[8], it became apparent that kuru and CJD were also of infectious
etiology. Indeed, by 1968, both human diseases had been successfully
transmitted to chimpanzees [9,10]. Despite these advances, the nature
of the scrapie agent continued to be the subject of intense debate for
many years. Because TSEs exhibit strain variation and long incubation
periods, it was argued that the agent could be a slow-virus [11].
However, direct proof for this “viral hypothesis” has been difﬁcult to
obtain [12]. Instead, it has been shown that the transmissible agent is
resistant to formalin (a chemical that inactivates viruses) and to various
other treatments that destroy nucleic acids, but not to proteolytic
digestion [13–15]. These and other developments ﬁnally led to the
enunciation of the “protein-only hypothesis” by Stanley Prusiner
(1982), according to which TSEs are caused by prions, small protein-
aceous particles capable of replicating in the absence of nucleic acids
[14,16].
The protein-only hypothesis has not remained uncontested. While
some continue to advocate the existence of an unidentiﬁed scrapie
agent [17–19], others see the notion of an infectious, self-replicating
protein as a clear violation of Crick's central dogma ofmolecular biology
[20], which excludes the ﬂow of biological information from protein to
protein. Notwithstanding the controversy, Prusiner's theory reasonably
accounts for the complex etiology of TSEs, the physicochemical
properties of the agent, and the existence of scrapie strains [3]. Today,
it is widely accepted that prions are largely – if not entirely – composed
of PrPSc, an abnormally folded isoform of the cellular prion protein
(PrPC) [21]. Themolecularmechanismbywhich normal PrPC “converts”
into infectious PrPSc is, however, poorly understood. It has been
proposed that PrPSc can associate with PrPC and induce its conversion
intomore PrPSc, triggering a chain reaction [22]. Alternatively, PrPSc and
PrPC may coexist in equilibrium until mutation or sporadic events favor
the formation of oligomeric PrPSc seeds, which undergo repeated
aggregation and fragmentation cycles [23]. In either case, the concept of
PrP conversion is central to the protein-only hypothesis because it
explains the ability of prions to replicate and propagate disease.
1.3. The prion protein
In 1982, PrPSc was identiﬁed as the major constituent of infective
fractions puriﬁed from hamster brain homogenates [24]. Subsequent
characterization revealed that thepathogenic proteinwashost-encoded
and not the product of a viral gene, as it had been assumed previously
[25,26]. It was also established that PrPSc is posttranslationally derived
from PrPC [27]. Thus, although the two isoforms differ greatly in their
spatial conformation [28], they have the same amino acid sequence and
are encoded by the same single-copy gene, Prnp [29]. Under normal
conditions, PrPC is a glycoprotein tethered to the outer plasma
membrane by a glycosylphosphatidylinositol (GPI) anchor. Its unique
molecular structure, studied by nuclearmagnetic resonance (NMR) and
crystallographic techniques, can be roughly divided into two halves: a
ﬂexible N-terminal domain rich in repetitive motifs, and a C-terminal
globular domain containing a characteristic array of threeα-helices and
two β-sheets. At the center of the polypeptide chain, a short
hydrophobic stretch connects the two major domains [30,31]. In
contrast, attempts to resolve the molecular structure of PrPSc have not
been successful.
Almost 30 years after the discovery of PrP, there is still no consensus
about what its physiological role might be. Since PrP has no obvious
similarities to known protein families, functional afﬁnities cannot be
inferred from amino acid sequence comparisons. Neither can organ- or
tissue-speciﬁc functions be hypothesized because PrP is widely
expressed in most adult and embryonic cell types [32–35]. Astonish-
ingly, the generation and analysis of PrP knockoutmice failed to provide
conclusive information about the physiological role of PrP, as these
animals develop and behave rather normally. Aside from a few subtleabnormalities, their only clear “phenotype” is their resistance to prion
infection [36]. It is probably not exaggerated to say that as many PrP
functions have been proposed as methods have been employed to
address this question. Thus, the list of putative PrP roles in vitro and in
vivo includes activities as diverse as cytoprotection from apoptosis [37]
and oxidative stress [38], olfactory behavior [39], copper metabolism
[40], neurogenesis [41], neurite outgrowth and neuronal survival [42],
lymphocyte activation [43], hematopoietic stem cell self-renewal [44],
synaptic function [45], activation of signal transduction [46], and
binding to cell adhesion molecules [47]. Unfortunately, it is not clear
howmany of these ﬁndings may be of actual physiological relevance. In
addition, it seems unlikely that a single molecular function of PrP could
account for such diverse biological roles.
The clear correlation between PrP misfolding and neurodegenera-
tion may suggest that PrPSc is the direct cause of prion disease.
Nevertheless, solid experimental evidence indicates that prions
cannot induce neuronal damage in the absence of PrPC. For instance,
PrP knockout mice are resistant to scrapie inoculation [48], even if
they carry PrPC-expressing neurografts [49], or if PrPC depletion is
induced postnatally [50]. Notably, transgenic mice expressing only a
GPI-anchorless version of PrP (thus unable to attach to the plasma
membrane) can efﬁciently replicate prions without developing prion
disease [51]. Altogether, these studies demonstrate that prion
neurotoxicity is not triggered by PrPSc itself, but by an activity of
PrPC at the cell surface. Accordingly, it has been proposed that prion
replicationmight cause PrPC to either lose a neuroprotective role, gain
a neurotoxic one, or subvert a neuroprotective role into a neurotoxic
one [52]. Therefore, a thorough characterization of PrPC function will
likely be instrumental in ascertaining the molecular basis of prion-
induced neurodegeneration.
1.4. Open challenges in prion biology and pathogenesis
The past ﬁve decades have seen remarkable achievements that
shaped our current understanding of TSEs. These include the
transmissibility of kuru and CJD to laboratory animals, the isolation
of the scrapie agent, the development of the protein-only hypothesis,
the identiﬁcation of PrP and its isoforms, and the study of prion
propagation in genetically modiﬁed mice. Yet, very little has been
learned about basic aspects of prion pathogenesis, such as the
mechanisms of PrP misfolding and prion replication, the physiological
function of PrP, or the cellular pathways through which prions induce
neurodegeneration. To this day, prion disorders remain incurable, and
neither early diagnostic methods nor anti-prion drugs have success-
fully been developed. Of special concern is the possibility that animal
prion diseases may be transmitted to humans via the food chain. In
fact, experimental evidence indicates that transmission of BSE to
humans was the likeliest cause for the appearance of a new variant
form of CJD (vCJD) [53,54]. These ﬁndings illustrate the need to ensure
food safety, not only through efﬁcient quality control but also by
experimentally assessing the risk of prion transmission across a wide
range of animal hosts.
So far, only beef and lambhavebeen identiﬁed aspotential sources of
dietary prion infections. Other major animal food sources like ﬁsh and
poultry appear to have remained free of prion contamination. However,
it is not clear whether these organisms are susceptible to prion
pathogenesis because TSE research has been carried out predominantly
in mice and other mammals. Therefore, the study of prion biology in
non-mammals, particularly in ﬁsh, is of great relevance to food safety.
Fish constitute a vital food resource for humans and animals worldwide
(Table 1), with direct impact on important economic activities like
ﬁshing and aquaculture.
In addition, several ﬁsh species have become valuable tools in
biomedical research. One of them, the zebraﬁsh (Danio rerio), is an
excellent model to study vertebrate development and the biology of
human disease. It hasmany advantages as a genetic system, such as its
Table 1
Commercially important ﬁsh species worldwide.
Source: Food and Agriculture Organization of the United Nations, Fisheries and
Aquaculture Department (http://www.fao.org/ﬁshery/en).
Common
name
Scientiﬁc
name
Main producers Main consumers
Salmon Salmo salar Chile, Norway, Scotland, USA,
Canada
Japan, Europe,
North America
Carp Cyprinus carpio Central Europe, China Austria, Germany,
Hungary, Poland
Tilapia Oreochromis
niloticus
niloticus
Africa, China, Papua New Guinea,
Philippines, Thailand, Indonesia
USA, China
Tuna Thunnus
albacores
Japan, Australia Japan, Australia
Catﬁsh Ictalutus
punctatus
USA, China USA, China
Trout Oncorhynchus
mykiss
Europe, USA, Chile Europe, USA,
Japan
Seabream Sparus aurata Mediterranean countries Europe
Sea bass Dicentrarchus
labrax
Mediterranean countries Europe
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zebraﬁsh embryos are transparent and develop externally, making
them amenable to detailed cellular analyses and genetic manipula-
tions. Moreover, the zebraﬁsh is rapidly emerging as a valuable tool in
clinical and pharmaceutical research aimed at drug discovery and
validation [56,57].
In this article, we review current knowledge about the occurrence of
PrPs, prions, and TSEs among vertebrates, focusing on recent advances
using ﬁsh models to characterize the physiological function of PrP and
the possible risk of prion transmission between ﬁsh and mammals.
2. Prion disease: a mammalian attribute?
2.1. PrP and prion-like “behavior”
Besides PrP, a handful of mammalian proteins appear to be able to
replicate in a prion-likemanner. Among them are themolecular culprits
of known neurodegenerative disorders, such as amyloid-β (Alzheimer's
disease), α-synuclein (Parkinson's disease), tau (Tauopathies) and
amyloid A (AA amyloidosis) [58]. Such observations are undoubtedly
intriguing, yet it still needs to be establishedwhether the rogue versions
of these proteins are indeed infectious and, like bona ﬁdeprions, capable
of spreading disease between individuals or even across species. In
fungi, at least six different proteins exhibit prion-like behavior, as
judged by their ability to propagate phenotypic traits between cells
without the need for nucleic acids [59]. However, these proteins have
neither structural nor functional similarities to PrP, or to one another.
Thus,while the studyof fungal prionshasprovidedvaluable information
about the molecular basis of prion conversion, it is not clear to what
extent this knowledge may apply to mammalian prion disease [60].
In addition tomammals, PrP homologues have also been identiﬁed in
birds [61], reptiles [62], amphibians [63] and ﬁsh [64], but not in
invertebrates. Comparison of amino acid sequences indicates that PrPs
have evolved differently in each vertebrate class. For instance, although
mammalian and avian sequences are strongly conserved, with similarity
scores of ~90% in each group, conservation between the two groups is
rather low (~30% similarity) [65,66]. Likewise, PrP sequences among
bony ﬁsh are relatively well conserved (50–60% similarity), but exhibit
only 20–25% similarity to mammalian sequences [67]. PrPs also exhibit
considerable variation in size, ranging from ~260 amino acids in
mammals and birds to ~600 amino acids in ﬁsh. Despite these large
differences in length and sequence, all vertebrate PrPs share the same
protein domains (Fig. 1) [67,68]. The degree of conservation varies
signiﬁcantly along the polypeptide, with the short hydrophobic stretch
and the repetitive domain being the most conserved and the mostdivergent regions of the protein, respectively. Remarkably, and despite
having undergone substantial sequence variation, the globular domain
retained its structural fold throughout evolution [67,69]. These observa-
tions strongly suggest that the globular domain carries out an important
function, which was already present in the last common ancestor of all
vertebrates.Whether prionbehaviorwas already an intrinsic attribute of
such primitive PrPs, or whether it appeared late in evolution remains to
be clariﬁed.
So far, TSEs have only been reported in mammals. This is not
surprising, since prion biology is aﬁeld primarily focused on the studyof
human diseases. Nevertheless, if PrP is intrinsically able to form
infectious prions, then its presence in non-mammals implies that
these animalswould – at least in theory– be susceptible to some formof
prion disease. Evaluating this scenario is particularly difﬁcult without
basic knowledge about PrP conversion and prion replication in non-
mammalian species. Moreover, it is not even clear what the eventual
manifestations of TSEs in ﬁsh or birds might be. Clearly, extensive
experimentation will be required to establish whether these organisms
can acquire and transmit prion disease.
2.2. Prion transmission and the species barrier
Prion transmission across different species is limited by the so-called
species barrier. Following primary inoculation between two species,
only some animals develop disease, with long incubation periods that
may reach the normal life span of the species. This phenomenon is
clearly illustrated by the resistance to TSE observed in rabbits, even after
intracranial inoculation with TSE agents of sheep, mouse and human
origin [70]. It has been suggested that the unique structural character-
istics of rabbit PrP make it less prone to pathogenic conversion [70,71].
Typically, species barriers become attenuated after serial passaging of a
prion strain, resulting in shortened incubation times and the consequent
adaptation of the host to the speciﬁc strain [72]. At the molecular level,
the efﬁciency of interspecies prion transmission appears to depend on
the degree of sequence and structural identity between the PrPs of the
two species involved [73]. For instance, wild type mice do not become
infected with hamster prions, whereas transgenic mice overexpressing
hamster PrP do [74]. However, BSE can effectively be transmitted to a
wide range of species and maintain its pathogenic characteristics, even
when passaged through an intermediate species carrying a different PrP
coding gene [75].
It has been proposed that every species harbors a number of possible
PrPSc conformational variants, with a thermodynamically “preferred”
conformation (strain) being the decisive factor for interspecies
transmission. According to this “conformational selection model” [76],
a signiﬁcant overlap between the preferred PrPSc conﬁgurations of two
species is likely to result in a relatively easy transmission of prions
between them [77]. On the contrary, two species not sharing common
PrPSc structures would have to overcome a considerable barrier to
transmission, and pathogenesis would not ensue without modiﬁcation
of the strain type. Therefore, evaluation of the prion transmission from
one species to another should also be based on the structural identity
between the host and donor PrP molecules and not exclusively on their
amino acid sequence [78].
The route of infection is another parameter affecting the magnitude
of species barriers. Most inoculation studies rely on the use of
intracranial injection because “natural” per os infection is usually less
effective [79,80]. Notably, even after homologous oral transmission of
BSE to cattle, animals may remain presymptomatic for 28 months,
despite the evident PrPSc deposition in their brains [81]. Although the
relative importance of the aforementioned factors has been extensively
studied, the outcome of an intra-species prion transmission cannot be
predicted in advance. It is noteworthy, that twodifferent TSE strains that
can effectively infect one species may present completely modiﬁed
transmissibilitypotentialswhen transmitted toa secondspecies. Thus, it
has been proposed that a more suitable term to describe these
Fig. 1. Fish andmammalian prion proteins. Upper panel: Fish possess two prion proteins, PrP-1 and PrP-2. Despite differences in sequence and length, ﬁsh andmammalian PrPs share
the same protein domains (drawn at scale). Lower panel: Recent studies indicate that a common involvement of vertebrate PrPs in cell–cell communication. In cultured cells, PrPs
elicit cell–cell contact formation. In the zebraﬁsh embryo, PrP-1 and PrP-2 are deployed during gastrulation and neural development, respectively. L = leader peptide, R= repetitive
domains, H = hydrophobic stretch, G = globular domain; orange triangles indicate the ends of the mature polypeptides. PrP localization at cell contacts is depicted in red.
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barriers” [76].
Recent data have led to the reconsideration ofmany parameters that
were thought to be indicative of a species barrier, such as the lack of
clinical symptoms. Interestingly, cases of subclinical infection in
mammals displaying neuropathological and biochemical abnormalities,
often including PrPSc accumulation, have been reported [82]. Thus,
prion-inoculated animals harboring high infectivity levels, and even
abnormal PrP aggregates in their brains, may under certain circum-
stances remain asymptomatic carriers throughout their lifetime.
Notably, subclinical disease has been reported even after homologous
transmission, for instance, in studies using the oral routeof infection and
low dosage inoculum [79,83,84].
3. Fish prion proteins
3.1. Duplicated PrPs in bony ﬁsh
PrP genes from land vertebrates have typically been cloned using
conventional procedures such as cDNA hybridization and PCR
screening. In contrast, ﬁsh PrP genes could not be isolated with
these methods due to their large DNA sequence divergence. The ﬁrst
ﬁsh PrP homologue was identiﬁed in Fugu rubripes by searching
genome databases for ORFs encoding key structural features of PrPs[64]. Subsequent cloning and sequencing of PrP genes in salmon, trout,
carp, stickleback, sea bream and zebraﬁsh [67,68,85,86] revealed that
bony ﬁsh possess two PrP orthologs, PrP-1 and PrP-2, which probably
arose during a ﬁsh-speciﬁc genome duplication [87]. Northern and
Western Blot analyses indicated that the ﬁsh proteins are expressed at
particularly high levels in adult ﬁsh brains, as well as in muscle, skin,
heart and gills [67]. Although quite variable in size and sequence, PrP-
1 and PrP-2 present characteristic features of mammalian PrPs: an N-
terminal signal peptide, conserved N-glycosylation sites, two cysteine
residues that form a disulphide bond, a central hydrophobic stretch,
and the C-terminal signal for the attachment of a GPI-anchor (Fig. 1).
An intriguing feature of ﬁsh PrPs is the presence of a highly conserved
motif of 13 amino acids in length between the repetitive region and
the hydrophobic stretch [67]; the structural or functional importance
of this motif is not evident from its sequence.
The repetitive domains of ﬁsh PrPs are easily recognizable but at the
same time clearly different from those of tetrapod PrPs. For example,
while a constant number of nearly identical octarepeats is typical for
mammals (or hexarepeats in birds), in ﬁsh the number and length of
degenerate repeats vary from species to species. Nevertheless, all PrP
repeats can be considered variations of two basic types of repeats (A and
B), which evolved differentially in every vertebrate class [67]. The
sequence of the globular domain also has diverged considerably
between ﬁsh and mammals, owing to high rates of amino acid
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inantly affect residues outside key structural motifs, and are not
expected to affect the globular fold [67].
Apart from PrP-1 and PrP-2, other genes partially resembling PrP
have been reported in ﬁsh. Originally described as PrP-like and Shadoo
[88,89], they are also known as PrP-1-rel and PrP-2-rel because of their
genomic location, directly downstream of PrP-1 and PrP-2, respec-
tively [67]. The encoded products are GPI-anchored polypeptides of
only 150–180 amino acids in length, expressed in brain tissues, and
containing the characteristic PrP hydrophobic stretch. Further
similarities to PrPs include a β-strand motif in PrP-rel-1 identical to
the ﬁrst β-strand of PrP, and the presence of degenerated B- and A-
like repeats in PrP-rel-2. This situation is reminiscent to that of Prnp
and its genomic neighbor Doppel. Thus, PrP-rels, like Doppel, may
have arisen from the tandem duplication of an ancestral PrP gene, and
then diverged as a result of high substitution rates and the differential
loss of motifs. Interestingly, although PrP-rels are predicted to be
unstructured proteins, their mammalian homologue Shadoo has
recently received attention because it appears to inﬂuence biological
and pathogenic activities of PrP in vivo [90,91].
3.2. Zebraﬁsh PrP-1 and PrP-2
The characterization of PrP homologues in the zebraﬁsh opened the
exciting possibility to study prion biology in a newmodel organism. Like
other bonyﬁsh, the zebraﬁsh has two prion protein orthologs, PrP-1 and
PrP-2, mapped to chromosomes 10 and 25, respectively [67]. Genomic
studies revealed that the two genes originated from the duplication of a
large chromosomal block that corresponds to those containing the Prnp
gene in mammals. That both gene copies are fully functional has been
biochemically conﬁrmed in ﬁsh and mammalian cells [92,93]. In these
studies, it was shown that the encoded polypeptides become properly
glycosylated and attached to the plasmamembrane via a GPI-anchor. As
is often the casewith duplicated genes [94], PrP-1 and PrP-2 are thought
to have retained complementary subsets of ancestral PrP functions.
Accordingly, zebraﬁsh PrPs have evolved distinct spatiotemporal
patternsof embryonic expression:whilePrP-1 is ubiquitously expressed
at high levels in very early stages of embryogenesis (blastula and
gastrula stages), PrP-2 is strongly upregulated at later stages in
developing neurons [92]. At later larval stages and into adulthood,
both genes continue to be expressed in the CNS, although PrP-2 atmuch
higher levels than PrP-1. The differences between the expression
patterns of PrP-1 and PrP-2 are due to the divergent evolution of DNA
transcriptional regulatory sequences upstream of each gene (Barth and
Málaga-Trillo, unpublished data). Interestingly, the expression of
zebraﬁsh PrPs (particularly PrP-2) in the developing nervous system
bears striking similarities to that of PrP in the mouse embryo [32]. It
remains to be determined if, like PrP-1, mammalian PrP plays a role
during blastula and early gastrula stages.
3.3. PrP loss of function phenotypes in zebraﬁsh embryos
One of the many experimental advantages of the zebraﬁsh is the
possibility to knockdown the expression of any given gene using
morpholino antisense oligonucleotides. When microinjected into
early ﬁsh embryos, morpholinos rapidly bind to their target mRNAs
and block their translation [95]. Recently, this method was success-
fully applied to study PrP loss of function in the zebraﬁsh. In contrast
to the absence of clear phenotypes in PrP knockout mice, knockdown
of zebraﬁsh PrPs revealed that these genes play essential roles during
distinct phases of embryonic development. Speciﬁcally, PrP-1 knock-
down causes lethal embryonic arrest during gastrulation, whereas
PrP-2 knockdown severely impairs brain development. Notably, the
PrP-1 phenotype can be rescued by PrP-1 or PrP-2 overexpression,
indicating that although the two proteins are expressed in different
developmental contexts, they share essentially the same biologicalactivity. Furthermore, the ability of mouse PrP to partially revert the
PrP-1 phenotype strongly suggests that this activity of PrP is
conserved between ﬁsh and mammals [92]. It is therefore surprising
that the loss of such an important functionwould not be evident in PrP
knockout mice, especially since PrP is expressed at high levels in the
mouse embryo. A plausible explanation for this discrepancy is that the
mouse knockout phenotype may become masked by genetic
compensation or developmental plasticity [96].
The relative simplicity of the zebraﬁsh gastrula makes the PrP-1
phenotype an excellent choice to analyze conserved mechanisms of
PrP function at the molecular and cellular levels. Detailed character-
ization of PrP-1 knockdown embryos revealed that the developmental
arrest was caused by the loss of tissue cohesion and the consequent
failure to carry out epiboly, an early morphogenetic cell movement.
Because epiboly relies on the control of cell–cell adhesion, this ﬁnding
led to the discovery that PrP-1 regulates the stability of E-cadherin/ß-
catenin adhesive complexes at the plasma membrane [92]. Ongoing
biochemical work indicates that the mechanism behind this effect is
the ability of PrP-1 to control the levels and membrane localization of
ß-catenin as well as the levels and phosphorylation state of Src-
related kinases (Sempou and Málaga-Trillo, in preparation). Related
unpublished in vivo pharmacological data suggest that PrP-1 acts to
prevent the degradation of some of these proteins.
These results are in agreement with long proposed roles of PrP as a
signal transduction molecule [46]. Concretely, the experiments with
zebraﬁsh gastrulae indicate that a complex signaling cascade is
initiated by the interaction between PrP-1 molecules across opposite
cell membranes. Accordingly, in vitro experiments show that ﬁsh,
amphibian, avian and mammalian PrPs share the intrinsic ability to
engage in such homophilic trans-interactions, promoting the forma-
tion of cell–cell contacts, and triggering intracellular signaling via Src-
related kinases [92]. Of special interest within the scope of this review
is the ﬁnding of heterologous interactions between zebraﬁsh and
mammalian PrPs [92], which raise the question of whether PrP
conversion and TSE transmission can take place across such distant
species.
Altogether, the combined work in zebraﬁsh embryos and
mammalian cells indicate that PrPs play crucial roles in cell–cell
communication (Fig. 1). These data are in line with the notion that PrP
provides protective signals required for neuronal growth and/or
survival [97,98]. Understanding the precise nature of such signals will
be crucial to uncover the early cellular mechanisms of prion
pathogenesis in the mammalian brain.
4. Risk of prion disease in ﬁsh
4.1. TSEs and the food chain
The appearance of BSE in Europe has been causally linked to the
common practice of feeding cattle withmeat and bonemeal (MBM) of
bovine origin [99]. Approximately 200,000 BSE cases were reported
between 1985 and 2000, and it has been estimated that roughly three
million infected animals could have entered the human food chain
before developing a clinical disease [81]. Due to its low cost and high
nutritional value, MBM has become an important ingredient in the
diet of non-ruminant livestock and farmed ﬁsh. Hence, there is the
theoretical risk that farmed animals unintentionally fed with prion-
contaminated MBM might develop TSEs or serve as asymptomatic
carriers of a disease [100]. Since BSE was initially reported, the
European Commission (EC) has implemented a comprehensive set of
TSE risk-reducing measures to protect humans from BSE, as well as to
control and eventually eradicate prion diseases in animals. Among
these, a total EU-wide feed ban on the use of rendered animal proteins
in the nutrition of all animals was imposed, with minor exceptions
(i.e. use of ﬁsh feeds in the diets of non-ruminants like pigs and
chicken).
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host without typical pathognomonic brain lesions, clinical disease or
fatality, has led to the conclusion that prion-infected individuals could
go undetected within an exposed population [100]. This implies that
farmed animals may carry the disease but not develop it until they are
slaughtered. Human consumption of meat from these animals would,
in turn, give rise to repeated infection cycles long before clinical signs
can be recognized. Moreover, the relatively recent discovery of
unconventional TSE phenotypes, such as atypical scrapie in sheep
and goats [101,102], and bovine amyloidotic spongiform encepha-
lopathy (BASE) in cattle [103], usually displaying decreased or altered
PrPSc resistance to proteolytic treatment and less pronounced clinical
signs, has further made it difﬁcult to deﬁne prion diseases in absolute
terms and thus, to implement effective rules to eliminate them.
4.2. Risk of prion transmission to ﬁsh
According to the aforementioned arguments, ﬁsh, poultry and pigs
represent potential candidate hosts for prion infection. In order to assess
the risk of prion transmission to ﬁsh, ﬁve main parameters should be
considered: 1. the potential use of prion-contaminated MBM as a
nutritional supplement in aquaculture, 2. the consumption of infected
farmed ﬁsh by humans, 3. the use of feeds or other products (i.e. gelatin,
milk replacers) derived fromTSE-affectedﬁsh formammalian or piscine
nutrition, 4. the use of ﬁshmeals cross-contaminated with MBM in
mammalian diets, and 5. the escape of infected ﬁsh, or the release of
infectedwaste from aquaculture facilities into themarine environment.
These scenarios are depicted in Fig. 2.
With ﬁsh mariculture turning into a very important and rich
protein source for humans, consumers may become concerned about
the possibility of farmed ﬁsh developing prion disease, or serving as
passive carriers of prion infectivity. All farmed ﬁsh receive commercial
feeds containing 40–55% protein, and since some of it is likely to be of
animal origin, the possibility of feed contamination with mammalian
prions cannot be excluded. Interestingly, in the late 1980s, total ﬁsh
feed production in the UK was in the order of 75,000 tons per year,
with the use of about 3750 tons of MBM in ﬁsh feed [104].
However, how realistic is the thesis that ﬁsh prion proteins may
misfold and form abnormal aggregates? The striking conservation of
structural motifs between mammalian and piscine PrP moleculesFig. 2. Prion diseases and the food chain. Potential scenarios for the transmission of
prions between mammals and ﬁsh are illustrated. Arrows indicate the direction of
possible transmission events.makes it rather difﬁcult to exclude such a possibility. Regarding the
convertibility potential of ﬁsh PrPs, it has been suggested that the
extended type A-repeat domain in sea bream PrP-1 and other ﬁsh PrPs
could confer on these proteins the ability to self-polymerize and
aggregate [85]. In addition, it has been noted that motifs similar to
those observed in ﬁsh PrPs can also be identiﬁed in unrelated proteins
such as the piscine annexin 11 and the mammalian lectin L-29 [77].
Notably, both these proteins display self-aggregation properties, and
annexin 11 is, like PrP, a neuro-speciﬁc membrane protein.
4.3. Transmission studies in commercially important ﬁsh species
At present, only a few studies have explored the experimental
transmission of TSEs to teleost ﬁsh. The ﬁrst attempts in this direction
involved the oral and parenteral inoculation of two commercially
important ﬁsh species, rainbow trout and turbot, with the 139A
mouse-adapted scrapie strain [105]. Although the ﬁsh displayed no
clinico-histopathological signs during the three month-experimental
period, a mouse bioassay revealed that they carried residual
infectivity. Speciﬁcally, mice intracranially inoculated with trout
intestinal extracts one day after oral challenge were positive for
brain PrPSc deposition approximately 200 days post inoculation (p.i.),
despite the absence of clinical symptoms. Similar results were
obtained whenmice were intracerebrally (i.c.) inoculated with spleen
extracts from trouts and turbots, 15 days after parenteral inoculation
of the ﬁsh with scrapiematerial. Finally, brain tissue from parenterally
inoculated turbots 15 and 90 days after challenge was also able to
elicit PrPSc accumulation in the brains of recipient mice, without
causing clinical disease.
Recently, we reported data on the oral transmission of BSE and
scrapie to gilthead sea bream (Sparus aurata) [106]. Interestingly, at
two years p.i., a number of ﬁsh that had been force-fed BSE- or
scrapie-infected brain homogenates developed abnormal plaque-like
deposits in their brains. Speciﬁcally, the brains of two out of ﬁve ﬁsh
inoculated with scrapie developed signs of abnormal protein
aggregation at 24 months p.i. These aggregates were positively
stained with polyclonal antibodies raised against ﬁsh PrPs, but
showed no proteinase K (PK)-resistance or Congo red birefringence
(Fig. 3A). The brains of the BSE-challenged ﬁsh, however, displayed a
much more striking picture, having already developed the ﬁrst signs
of abnormal deposition at eight months p.i. A general progression in
size, PK-resistance and morphological features was observed there-
after, resulting in an impressive number of aggregates in all the brain
regions examined at 24 months p.i. Three out of ﬁve ﬁsh sacriﬁced at
this time point showed 500–800 deposits per brain section each, 70–
85% of which were PK-resistant and had a mean diameter of 30 μm.
These aggregates were PAS-positive, congophilic and birefringent in
polarized light, indicating an amyloid or amyloid-like ﬁbrillar
structure (Fig. 3B). In contrast to the TSE-challenged individuals, no
signs of abnormal aggregation or any other lesions were observed in
the brains of the control ﬁsh “challenged” with bovine or ovine brain
homogenates prepared from healthy animals. Altogether, the devel-
opment of abnormal brain deposits in BSE-challenged sea bream
constitutes an unprecedented histopathology in ﬁsh.
4.4. Neuropathology in TSE-challenged sea bream
The lesions observed in the brains of the BSE-infected sea bream
share some remarkable similarities with those typically seen in prion-
affected mammalian brains. For instance, the deposits in ﬁsh brains
were only detectable where neuronal parenchyma was present, a
feature greatly resembling the localization of prion amyloid plaques in
mammals [107]. The most extensively affected regions included the
cerebellum (which displayed a mammal-like deposition motif [108]),
the lateral nucleus of the ventral telencephalic area (a ﬁsh counterpart
to the basal nucleus of Meynert in mammals [109]), the lateral
Fig. 3. Experimental transmission of prions between mammals and ﬁsh. Inoculation of ﬁsh with ovine (A), bovine (B) and mouse (C) prions and their various outcomes. The
photographs on the upper right corner illustrate the development of abnormal amyloid deposition in the optic tectum of BSE-challenged sea bream, using the periodic acid Schiff
(PAS) staining reaction. The right image (scale bar=10 μm) is a zoom-in of the lesion indicated in the left image (scale bar=100 μm). i.c., intracerebrally.
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[110]), and ﬁnally the thalamus and diencephalon. Notably, no
spongiosiswasobserved in anyof thebrain regionsexamined.However,
cases of TSE subtypes that develop little or novacuolationhave alsobeen
reported for human prion diseases [111]. Interestingly, the neurode-
generation observed in BSE-challenged sea bream affected only
neurites, as opposed to the “classically deﬁned” degeneration of
neuronal somata. Based on the morphological progression of the
abnormal deposits and the level of neurite involvement, aggregates
were classiﬁed into two main categories. “Pre-mature” deposits,
observed mostly at earlier time points and consisting mainly of
dystrophic neurites that have lost their coherence, appear to mark
initial stages of neurodegeneration. “Mature” deposits, observed
24 months p.i., seem to result from the complete deconstruction of
ﬁbers, leading to the development of a more homogenous and
ﬂocculated extracellular material, with increased PrP-immunoreactiv-
ity, congophilia and birefringence in polarized light. The two types of
aggregates in the brains of BSE-challenged sea bream could be
interpreted as different stages of pathogenesis, with the former
temporally preceding the latter. For scrapie-challenged sea bream, the
distribution andmorphology of the observed neuropathology could not
be evaluated and classiﬁed as mentioned earlier, due to the limited
number of ﬁsh developing abnormal deposits in this group.
4.5. Absence of “clinical symptoms” in ﬁsh: presymptomatic carrier
state?
Visual examination of challenged ﬁsh throughout the post
inoculation period revealed no signs of altered swimming behavior
or eating habits. However, previous studies have shown that species
once thought to be resistant to certain TSE strains can be life-longcarriers of the infection without ever developing a clinical disease. For
example, the absence of clinical symptoms has been reported in mice
following the primary transmission of sheep and hamster scrapie.
However, sequential passage of infectious material did result in the
development of clinical disease [82]. Interestingly, differential
susceptibility to speciﬁc pathogens is also known among piscine
species. For instance, closely related ﬁsh species may exhibit
differential resistance to viral infections, as illustrated by the
development of clinical disease in sea bass but not in sea bream
infected with nodavirus [112,113]. On the other hand, the absence of
clinical symptoms in BSE-challenged sea bream could be related to the
remarkable ability of teleost ﬁsh to continuously produce new
neurons throughout their lifetime. It is well known that adult ﬁsh
can regenerate destroyed retinal tissue, optic nerve axons, and
degenerated brain stem neurites, resulting in functional recovery of
these structures [114,115]. Given the fact that farmed ﬁsh remain in
aquaculture facilities up to 20 months before reaching the required
commercial weight, the lack of clinical disease in infected animals
may become a crucial issue of unanticipated relevance for public
health.
4.6. Differential susceptibility of ﬁsh species to prion infection
In a parallel study, we inoculated European sea bass (Dicentrarchus
labrax) with the same infectious material, namely BSE and scrapie.
Interestingly, in contrast to the sea bream, none of the challenged
individuals showed any clinical symptoms or histopathological
evidence of abnormal deposition at any point throughout the time
course of the study. Sea bass and sea bream are both Perciformes, the
largest class of teleosts. Although they belong to different families,
Sparidae (sea bream) and Moronidae (sea bass), the two species are
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the amino acid sequence of sea bass PrP is not available, it is not clear
how it might differ from that of sea bream PrP. However, the two
proteins display different reactivities against anti-ﬁsh PrP antibodies.
Conceivably, such differences could confer on the sea bass PrP
resistance to the PrPSc in the inoculum, and thus, reinforce the
“transmission barrier” in these experiments.
Another factor possibly involved in the different reaction of the
two species to prion inoculation might be the ease with which
exogenous PrPSc can cross the intestinal barrier and reach the CNS
[116]. In teleosts, like in other vertebrates, oral pathogens are initially
confronted by activated immune cells on the enteric wall. Macro-
phages, whose efﬁciency contributes to the resistance against
pathogens, play an important role in this process. While in sea bass,
enteric phagocytes seem to become extensively activated upon
microbial attack [117], it has been reported that the intestinal mucosa
of the sea bream may be relatively permissive to infection by certain
bacteria [118].
Although plausible, these hypotheses do not entirely explain the
differential sensitivity of the two species to prion infection, since cases
of pathogenesis in which the clinically affected species is the sea bass
and not the sea bream are also known [112]. It is noteworthy,
however, that the different susceptibility of the two species can be
regarded as an internal control in our transmission experiments.
Speciﬁcally, the fact that despite the close relationship between the
two species, only sea breamwere affected, strengthens the hypothesis
that the observed neuropathology represents a novel piscine
amyloidosis triggered by mammalian prions. Thus, transmissibility
of prions to ﬁsh exhibits species speciﬁcity, a common feature of TSEs.
4.7. Possible routes of neuroinvasion: tissues harboring infectivity
Immunohistochemical examination of peripheral tissues from TSE-
inoculated sea bream including spleen and intestine revealedno signs of
abnormal protein accumulation at any of the time points tested.
Therefore, it is likely that the transit of prions from the ﬁsh
gastrointestinal (GI) tract to the CNS might have occurred long before
the ﬁrst time point of sacriﬁce, perhaps only a few hours or days after
oral challenge, leaving no trace of infectivity in the peripheral tissues
tested thereafter. Transmission studies in rainbow trout and turbot have
shown that speciﬁc bindingof exogenousPrPSc (139Ascrapie strain) can
be detected in the intestinalmucosa for up to seven days p.i., despite the
absence of active uptake by the epithelial cells [105,119].
Preliminary data from a more recent study demonstrate the
importance of residual infectivity, suggesting that after oral challenge
with the ME7 mouse-adapted scrapie, prions can cross the intestinal
wall of the sea bream and be delivered from the peritoneal cavity into
the spleen (Figueras et al., unpublished data). More speciﬁcally,
inoculated ﬁsh were sacriﬁced at regular time points, and various
tissues, including spleen and intestine, were used to intracranially
inoculate mice (Fig. 3C). The TSE-challenged ﬁsh never showed
histopathological or clinical symptoms throughout the 18 month-
experimental period. However, serial passage to mice of tissues from
ﬁsh sacriﬁced one week p.i. induced vacuolation in the brains of some
of the mice, 300 days after the intracranial inoculation. Concretely,
spongiosis without clinical disease was detected in ﬁve out of 19
recipient mice inoculated with scrapie-infected ﬁsh spleens, and in 12
out of 17 individuals challenged with scrapie-infected ﬁsh intestines.
These ﬁndings suggest, on one hand, that the TSE agent might have
been able to reach the ﬁsh brain in a remarkably short period of time,
either after peripheral propagation or even by direct neuroinvasion.
On the other hand, this study emphasizes the need for a thorough
examination of peripheral tissues in asymptomatic individuals
following prion inoculation.
There is no doubt that the intestine represents the main entry point
for oral pathogens. In zebraﬁsh, for example, it has been proposed thatthe GI tract may serve as a potential portal for exogenous PrPSc, due to
the high PrPmRNA levels detected in the posterior intestine of zebraﬁsh
larvae [68]. In mammals, studies have shown that the pathogenic agent
may invade the CNS directly, by exploiting the extended autonomous
intestinal innervation [120]. In particular, it has been proposed that BSE
neuroinvasion may take place via the parasympathetic nerve ﬁbers of
the vagusnerve into the brain stemof orally-challenged cattle [81]. Such
a route of dispersion requires the adequate expression of endogenous
PrPC within the peripheral nervous system [121]. In the sea bream,
immunohistochemical examination of intestinal tissue revealed three
main regions of intense PrP-immunopositivity, namely the serosa, the
myenteric plexus (corresponding to Auerbach's plexus in mammals)
and the submucous plexus (a homologue to mammalian Meissner's
plexus). Both the myenteric and the submucous plexus contain many
parasympathetic nerves and ganglia, one of which is a nucleus of the
vagus nerve running to the medulla oblongata in the brain stem of
mammals and teleosts. The hypothesis that the infectious agent might
use the enteric nervous system to invade the ﬁsh CNS is supported by
the progressive changes observed in the regional distribution of
abnormal deposits in sea bream brain [81]. Initially, the region affected
is the posterior part of the brain,with the brain stemdisplaying themost
severe lesion proﬁle. Subsequently, anterior anatomical regions show
signs of abnormal aggregation as well, although posterior brain areas
continue to be affected. Interestingly, it has been proposed that direct
neuroinvasion of the infectious agent following per os challenge might
be related to the absence of clinical symptoms and the reduced attack
rate of the transmitteddisease [122], anobservation that is in agreement
with the asymptomatic amyloidosis developed by BSE-challenged sea
bream.
5. Future directions
5.1. Monitoring for infectious neurodegenerative disease in farmed ﬁsh
The rapid worldwide expansion of ﬁsh farming calls for the
implementation of efﬁcient measures to ensure animal health and
food safety. The fact that pathogens can spread considerablymore easily
through ﬂowing water than between land animals is one of the main
difﬁculties when dealing with aquatic diseases. Over the last years, the
aquaculture industry has been faced with an increasing number of
infectious diseases affecting both farmed and feral populations.
Surveillance and monitoring programs have therefore been developed
in many countries, in an attempt to prevent and control the emergence
of new ﬁsh pathologies [123]. The list of notiﬁable diseases varies
depending on the speciﬁc needs of each region. In Europe, all countries
are asked to comply with the Council Directive (2006/88/EC) on health
requirements for aquaculture animals. Nevertheless, it would be
sensible to enrich the list of large-scale spot checks in ﬁsh farms by
including the histological examination of ﬁsh brains, in order to detect
possible signs of feed-induced or even spontaneous PrPSc amyloidosis.
As described earlier, BSE-infected sea bream developed the ﬁrst signs of
abnormal aggregation already at eightmonthsp.i., a timeperiod that lies
within the grow-out phase of ﬁsh breeding. Moreover, the fact that
these animals remained asymptomatic throughout the experimental
period raises the possibility that affected ﬁsh may generally go
undetected before ending up on our plates.
5.2. Further transmission studies in commercially important ﬁsh species
Gilthead sea bream and European sea bass are the two most
important farmed ﬁsh in the Mediterranean Sea, with the main
producers being Greece, Turkey, Spain, France and Italy. In 2004, the
annual production levels of both species reached 160,000 tons
worldwide. Therefore, assessing the risk of TSE transmission to these
ﬁsh is an issue of major importance for public health. On a global scale,
the practice of aquaculture is experiencing steady growth rates, driven
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projections by the Food and Agriculture Organization of the United
Nations (FAO), the global production of farmed ﬁsh will have to reach
80 million tons by 2050, in order to maintain the current level of ﬁsh
consumption per capita. Amazingly, not all countries have introduced
laws to regulate the use of rendered mammalian proteins for ﬁsh
nutrition and, in somecases, those thathave, have incurred inminor and
major violations [124]. Hence, the likelihood that contaminated MBMs
might have been inadvertently fed to farmedﬁsh is considerably high. In
this regard, the amyloidosis observed in the brains of BSE-fed sea bream
demonstrates that certain ﬁsh species can develop neuropathology
following ingestion of prion-contaminated meals. Therefore, further
transmission studies with other commercially important ﬁsh species,
including salmon (Salmo salar), trout (Oncorhynchus mykiss), and carp
(Cyprinus carpio) should be conducted in order to evaluate the
likelihood of acquiring TSEs upon consumption of infected feeds
(Fig. 4). In addition, primary TSE transmission studies in piscine species
that are considered future candidates for mariculture would be
advisable, especially those closely related to sea bream, such as the
common dentex (Dentex dentex, Sparidae) and the red porgy (Pagrus
pagrus, Sparidae).
5.3. Zebraﬁsh as a model for prion pathobiology
Clearly, transmission experiments in commercially important
species are necessary to directly assess the risk that TSE-infectedFig. 4. Future scenarios for transmission studies. Examples of primary and secondary inocu
mammalian species. Tg = transgenic, wt = wildtype, ZF = zebraﬁsh, boPrP = bovine PrP,ﬁsh would pose to humans. On the other hand, addressing the cellular
andmolecular aspects of prion transmission to ﬁsh requires the use of
established model organisms. The zebraﬁsh is best ﬁtted for this
purpose, not only because of its well-characterized neuroanatomy
and neural development, but also because of the availability of useful
research tools, such as mutant strains, GFP-transgenic lines, speciﬁc
antibodies, cell lines and a fully sequenced genome. Additionally,
zebraﬁsh larvae are optimally suited for the study of neurological
diseases because they display quantiﬁable neuropathological and
behavioral phenotypes similar to those observed in humans [125]. It
would be particularly interesting to know whether scrapie or CJD
prions can be efﬁciently inoculated to transgenic zebraﬁsh expressing
mouse or human PrPs. Similarly, expression of pathogenic PrP
mutants in wildtype and transgenic ﬁsh could be of great value in
elucidating the genetic basis of prion disease. Engineering of these
animals, currently underway, will provide an ideal tool to systemat-
ically analyze prion replication in ﬁsh brains, as well as the
development of PrP aggregates, brain lesions, and possibly clinical
disease. Another fascinating perspective is the possibility to study the
effect of exogenously added prions on zebraﬁsh embryos. Such
experiments could signiﬁcantly facilitate the analysis of PrPC and PrPSc
behavior in vivo, thus contributing valuable insights into the
relationship between prion conversion and PrP dysfunction. Alto-
gether, transmission experiments in zebraﬁsh could help to effective-
ly evaluate the susceptibility of ﬁsh to TSEs, as well as the mechanistic
link between PrP function and prion pathogenesis.lation studies required for the evaluation of prion transmissibility between piscine and
ovPrP = ovine PrP, huPrP = human PrP, moPrP = mouse PrP.
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Issues of prion transmissibility between ﬁsh andmammals need to
be given full consideration because of the possibility that ﬁsh fed with
prion-contaminated MBM may further transmit TSEs through the
food chain. To evaluate this scenario, secondary transmission
experiments between BSE-affected ﬁsh brains and mice carrying the
bovine Prnp gene are currently underway. Further studies in
transgenic ﬁsh will also help assess the risk of potential transmission
of piscine amyloidoses to mammals or to other ﬁsh species (Fig. 4).
For instance, the use of transgenic zebraﬁsh carrying the bovine Prnp,
or mice carrying the gene coding for ﬁsh PrP on a PrP knockout
background would answer a plethora of questions concerning not
only host-related pathogenic determinants but also the speciﬁc
conditions required for certain intra-species transmissions.
The discovery of residual prion infectivity in ﬁsh intestines and
spleens is also a matter of great concern, as it suggests that even ﬁsh
species resistant to prion infection might harbor infectivity shortly
after ingestion of contaminated meals, thus being able to transmit the
disease to consumers. Similar studies should be undertaken employ-
ing a variety of ﬁsh species and TSE strains, including atypical scrapie
and BSE, to assess residual infectivity levels not only in spleen and
intestine, but also in blood and other “high risk” tissues (Fig. 4).
Furthermore, bioassays should also include “humanized” mice in
order to directly assess the risk of transmission to humans.
Another basic question that requires further clariﬁcation is the
convertibility potential of ﬁsh PrPs. Ongoing experiments using the
sensitive protein misfolding cyclic ampliﬁcation (PMCA) method
[126,127] may reveal whether piscine PrPs have the intrinsic ability to
misfold and aggregate. In addition, the use of TSE-infected cell lines
could become an important tool to investigate possible molecular
interactions between mammalian PrPSc and ﬁsh PrPC, leading to the
conversion of piscine PrPs. Aside from transmissibility and convert-
ibility issues, the composition of the deposits found in the brains of the
BSE-challenged sea bream deserves further examination. Concretely,
the identiﬁcation of other aggregated molecules in brain deposits
could help deﬁne the properties of these novel amyloid plaques, and
perhaps their mechanistic connection to neurodegeneration. For
instance, previous data on the composition of amyloid deposits
present in degenerating neuronal tissue have suggested that the
components of such aggregates may represent the outcome of the
degeneration process rather than the cause of neuronal cell death
[128]. Thus, the study of novel proteinaceous deposits may contribute
new leads to the debate about the causal link between neurotoxicity
and protein oligomerization.Fig. 5. Exploring the roles of PrP in health and disease. It has been proposed that neuronal
remains to be clariﬁed how the various cellular and molecular processes inﬂuenced by PrP5.5. Dissecting the physiological roles of PrP in the zebraﬁsh
The molecular basis of prion disease is closely associated with the
structural and functional properties of PrP. Therefore, deep under-
standing of prion pathogenesis in ﬁsh and mammals cannot be
reached without basic knowledge about the physiological roles of PrP.
The knockdown phenotypes described in zebraﬁsh constitute the ﬁrst
experimental evidence that the lack of PrP can cause dramatic
abnormalities in a whole organism [92]. In addition, the ﬁnding that
PrPs regulate cell–cell communication via known cellular pathways
provides an ideal opportunity to establish how PrP may exert its
proposed neuroprotective role (Fig. 5). It is noteworthy that some of
the molecules affected in PrP-1 knockdown embryos (Src-kinases, E-
cadherin, β-catenin, etc.) are not only essential for early zebraﬁsh
development but also play important roles in neuronal function and
during neurodegeneration [96]. Therefore, it will be crucial to further
characterize the signaling pathways under the control of PrP-1 using
biochemical, cell biological, proteomic and imaging tools. Such
experiments are currently being carried out in ﬁsh embryos and
embryonic stem cells. Ideally, this basic knowledge should be
integrated into the design and interpretation of studies addressing
the function of PrP in mammalian cells, as well the experimental
transmission of prion disease between ﬁsh and mammals.
Characterization of the PrP-2 knockdown phenotype is currently in
progress. Preliminary results show that PrP-2 is required for the
proliferation and differentiation of different groups of embryonic
neurons (Málaga-Trillo and Luncz, unpublished data). A similar
phenotype has been reported for PrP knockout mice [41], although
the defect does not impair neural development to the extent seen in
the zebraﬁsh [92]. Because PrP-2 also shares the ability to elicit cell–
cell adhesion and intracellular signaling, it is likely to regulate neural
development via the same molecular pathways controlled by PrP-1 in
the early gastrula. Thus, morphological and molecular analyses of the
PrP-2 phenotype may provide valuable mechanistic insights into the
roles of PrP during neuronal differentiation, axon growth, and
synaptogenesis. Integrating the emerging zebraﬁsh data within the
vast amount of information available from mammalian cells and
knockout mice promises to become a lengthy but rewarding task.
6. Concluding remarks
For many years, prion researchers have relied heavily on the use of
mammalian models as experimental systems. This strategy, and
particularly the development of genetically modiﬁed mice, has led to
outstanding discoveries in the ﬁeld. At the same time, thedeath results from failure by PrP to provide an unknown neuroprotective function. It
in vivo may converge into such a neuroprotective role.
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exposed the need for new animal models in prion biology. Recently,
researchers have explored the utility of ﬁsh to address questions
concerning the physiological roles of PrP and the risk of TSEs in these
organisms. An interesting picture has emerged, suggesting that
transmission of prions could potentially take place between com-
mercially important ﬁsh and mammals, although the implications of
these ﬁndings for human and animal health remain to be clariﬁed.
Much remains to be done in order to conﬁrm or rule out the existence
of bona ﬁde prions in ﬁsh. Nevertheless, the use of ﬁsh models in TSE
researchwill likely uncover novel aspects of prion transmission across
a wide range of hosts, relevant to human health. In addition, the
ﬁnding that ﬁsh and mammalian PrPs share important roles in cell–
cell communication might help elucidate the molecular mechanisms
by which prions induce neuronal death, setting the stage for the
identiﬁcation of new anti-prion therapeutic targets.
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